A Phase 1 interventional study of Tirabrutinib in Relapsed/Refractory B-cell Malignancies, sponsored by Gilead Sciences. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-24.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to determine the long-term safety and tolerability of tirabrutinib in adults with relapsed/refractory B-cell malignancy who have tolerated and achieved stable disease or improved with tirabrutinib treatment while enrolled in a prior (parent study) tirabrutinib study (NCT01659255). The dosing regimen will be based on the prior dosing regimen from the parent study.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed/refractory chronic lymphocytic leukemia (CLL) received tirabrutinib 40 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
Drug: Tirabrutinib
Tablets or capsules administered orally
Also known as: ONO/GS-4059
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)
Treatment-emergent AEs were defined as one or both of the following: * Any AEs with an onset date on or after the study drug start date of parent study and no later than 30 days after permanent discontinuation of study drug in this rollover study; * Any AEs leading to premature discontinuation of study drug.
Time frame: First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study
Percentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities
Treatment-emergent marked laboratory abnormalities were defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of study drug plus 30. If the relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the timeframe specified above will be considered treatment-emergent marked abnormalities. Laboratory assessments included tests for Chemistry, Hematology, Coagulation and Urinalysis.
Time frame: First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study
Overall Response Rate (ORR)
ORR was defined per Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for CLL and Cheson, 2007 criteria for NHL as percentage of participants who achieve partial response (PR) or complete response (CR) in either parent or roll-over study. CLL:CR: lymphocytes (Ly) \<4\*10\^9/L, no lymphadenopathy,normal spleen and liver size,absence of disease, absolute neutrophil count (ANC) \>1.5\*10\^9/L,platelets ≥100\*10\^9/L, hemoglobin (Hb) \>110 g/L,bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy,size of liver and spleen, bone marrow infiltrates;and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters (LD) of all index lesions,no new lesions;no increase in size of liver or spleen;persistence of bone marrow involvement in participant who meets other criteria for CR.
Time frame: Up to 39 months in parent study and up to 60 months in rollover study
Duration of Response (DOR)
DOR was defined per IWCLL 2008 criteria for CLL and Cheson, 2007 criteria for NHL as the interval from first documentation of CR or PR to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause in subjects who achieve a response. CLL:CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of the LD of all index lesions, no new lesions; no increase in size of liver or spleen; persistence of bone marrow involvement in participant who meets other criteria for CR.
Time frame: From first documentation of CR or PR to the first documentation of disease progression or death from any cause up to 39 months in parent study and up to 60 months in the rollover study
Progression-free Survival (PFS)
PFS was defined per IWCLL 2008 criteria for CLL and Cheson 2007 criteria for NHL as the interval from date of the first dose of tirabrutinib on the parent study to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause. Progressive disease (PD) in CLL: Lymphadenopathy, or appearance of any new lesion/organomegaly, \> 50% increase in the size of the liver and/or spleen, Decrease in platelet count or hemoglobin attributable to CLL per IWCLL, Transformation to a more aggressive histology (eg, Richter syndrome). PD in NHL: Cheson, 2007: Appearance of new lesion or increase by \>50% of previously involved sites from nadir, Transformation to a more aggressive NHL histology.
Time frame: From first dose of tirabrutinib in the parent study (NCT01659255) to the first documentation of disease progression or death from any cause up to 99 months
Overall Survival (OS)
OS is defined as the interval from date of the first dose of tirabrutinib on the parent study until death from any cause.
Time frame: From first dose of tirabrutinib in the parent study (NCT01659255) until death from any cause up to 99 months
Participants were enrolled at study sites in the United Kingdom and France. The first participant was screened on 10 September 2015. The last study visit occurred on 30 December 2020.
| Milestone | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 3 | 7 | 2 | 1 | 2 | 2 | 1 | 3 | 4 | 2 |
| Completed | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Not completed | 2 | 3 | 7 | 0 | 1 | 2 | 2 | 0 | 3 | 4 | 2 |
| Withdrew: Progressive disease | 1 | 2 | 3 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 1 |
| Withdrew: Investigator's discretion | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
Treatment-emergent AEs were defined as one or both of the following: * Any AEs with an onset date on or after the study drug start date of parent study and no later than 30 days after permanent discontinuation of study drug in this rollover study; * Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Treatment-emergent marked laboratory abnormalities were defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of study drug plus 30. If the relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the timeframe specified above will be considered treatment-emergent marked abnormalities. Laboratory assessments included tests for Chemistry, Hematology, Coagulation and Urinalysis.
| percentage of participants | Tirabrutinib 40 mg Once Daily (CLL) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities | 100.0 | 100.0 | 66.7 | 71.4 | 100.0 | 100.0 | 100.0 | 50.0 | 0 | 33.3 | 50.0 | 50.0 |
ORR was defined per Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for CLL and Cheson, 2007 criteria for NHL as percentage of participants who achieve partial response (PR) or complete response (CR) in either parent or roll-over study. CLL:CR: lymphocytes (Ly) \<4\*10\^9/L, no lymphadenopathy,normal spleen and liver size,absence of disease, absolute neutrophil count (ANC) \>1.5\*10\^9/L,platelets ≥100\*10\^9/L, hemoglobin (Hb) \>110 g/L,bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy,size of liver and spleen, bone marrow infiltrates;and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters (LD) of all index lesions,no new lesions;no increase in size of liver or spleen;persistence of bone marrow involvement in participant who meets other criteria for CR.
| percentage of participants | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 100.0 (15.8 to 100) | 100.0 (29.2 to 100) | 100.0 (59 to 100) | 100.0 (15.8 to 100) | 100.0 (2.5 to 100) | 100.0 (15.8 to 100) | 100.0 (15.8 to 100) | 100.0 (2.5 to 100) | 100.0 (29.2 to 100) | 100.0 (39.8 to 100) | 50.0 (1.3 to 98.7) |
DOR was defined per IWCLL 2008 criteria for CLL and Cheson, 2007 criteria for NHL as the interval from first documentation of CR or PR to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause in subjects who achieve a response. CLL:CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of the LD of all index lesions, no new lesions; no increase in size of liver or spleen; persistence of bone marrow involvement in participant who meets other criteria for CR.
| months | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) | NA (61.7 to NA) | 27.0 (26.3 to 42.3) | 57.7 (39.8 to NA) | NA (76.6 to NA) | NA (NA to NA) | 33.6 (25.7 to 41.4) | NA (33.6 to NA) | NA (NA to NA) | 63.2 (23.9 to 63.2) | 71.4 (53.6 to NA) | 37.0 (37.0 to 37.0) |
PFS was defined per IWCLL 2008 criteria for CLL and Cheson 2007 criteria for NHL as the interval from date of the first dose of tirabrutinib on the parent study to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause. Progressive disease (PD) in CLL: Lymphadenopathy, or appearance of any new lesion/organomegaly, \> 50% increase in the size of the liver and/or spleen, Decrease in platelet count or hemoglobin attributable to CLL per IWCLL, Transformation to a more aggressive histology (eg, Richter syndrome). PD in NHL: Cheson, 2007: Appearance of new lesion or increase by \>50% of previously involved sites from nadir, Transformation to a more aggressive NHL histology.
| months | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | NA (63.5 to NA) | 44.0 (28.1 to 44.1) | 59.5 (41.6 to NA) | NA (78.5 to NA) | NA (NA to NA) | 35.4 (27.6 to 43.3) | NA (39.1 to NA) | NA (NA to NA) | 65.0 (25.8 to NA) | 73.2 (57.3 to NA) | NA (38.9 to NA) |
OS is defined as the interval from date of the first dose of tirabrutinib on the parent study until death from any cause.
| months | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (44.8 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (40.8 to NA) | NA (NA to NA) | NA (65.0 to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over All-Cause Mortality: Enrollment up to 39 months in parent study and up to 61months in the rollover study Adverse Events (AE): First dose of tirabrutinib up to 36 months in the parent study and up to 61 months in the rollover study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirabrutinib 40 mg QD (CLL) | — | 0/1 (0%) | 1/1 (100%) |
| Tirabrutinib 80 mg QD (CLL) | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Tirabrutinib 160 mg QD (CLL) | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Tirabrutinib 320 mg QD (CLL) | 1/7 (14.3%) | 5/7 (71.4%) | 7/7 (100%) |
| Tirabrutinib 400 mg QD (CLL) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Tirabrutinib 500 mg QD (CLL) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Tirabrutinib 600 mg QD (CLL) | 0/2 (0%) | 1/1 (100%) | 1/1 (100%) |
| Tirabrutinib 300 mg BID (CLL) | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Tirabrutinib 160 mg QD (NHL) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Tirabrutinib 320 mg QD (NHL) | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Tirabrutinib 480 mg QD (NHL) | 1/4 (25%) | 4/4 (100%) | 4/4 (100%) |
| Tirabrutinib 600 mg QD (NHL) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Tirabrutinib 40 mg QD (CLL) | Tirabrutinib 80 mg QD (CLL) | Tirabrutinib 160 mg QD (CLL) | Tirabrutinib 320 mg QD (CLL) | Tirabrutinib 400 mg QD (CLL) | Tirabrutinib 500 mg QD (CLL) | Tirabrutinib 600 mg QD (CLL) | Tirabrutinib 300 mg BID (CLL) | Tirabrutinib 160 mg QD (NHL) | Tirabrutinib 320 mg QD (NHL) | Tirabrutinib 480 mg QD (NHL) | Tirabrutinib 600 mg QD (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H3n2 influenzaInfections and infestations | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| SepsisInfections and infestations | 0/1 | 0/2 | 0/3 | 1/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/1 | 0/2 | 0/3 | 1/7 | 1/2 | 0/1 | 0/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| Anal haemorrhageGastrointestinal disorders | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 0/1 | 1/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| PyrexiaGeneral disorders | 0/1 | 0/2 | 1/3 | 2/7 | 1/2 | 0/1 | 0/1 | 0/2 | 0/1 | 0/3 | 1/4 | 0/2 |
| InfluenzaInfections and infestations | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/1 | 0/3 | 0/4 | 1/2 |
| Lower respiratory tract infectionInfections and infestations | 0/1 | 1/2 | 1/3 | 2/7 | 0/2 | 0/1 | 0/1 | 1/2 | 0/1 | 0/3 | 2/4 | 0/2 |
| Ophthalmic herpes zosterInfections and infestations | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/1 | 0/3 | 0/4 | 1/2 |
| Event | Tirabrutinib 40 mg QD (CLL) | Tirabrutinib 80 mg QD (CLL) | Tirabrutinib 160 mg QD (CLL) | Tirabrutinib 320 mg QD (CLL) | Tirabrutinib 400 mg QD (CLL) | Tirabrutinib 500 mg QD (CLL) | Tirabrutinib 600 mg QD (CLL) | Tirabrutinib 300 mg BID (CLL) | Tirabrutinib 160 mg QD (NHL) | Tirabrutinib 320 mg QD (NHL) | Tirabrutinib 480 mg QD (NHL) | Tirabrutinib 600 mg QD (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/1 | 0/2 | 1/3 | 2/7 | 1/2 | 0/1 | 0/1 | 1/2 | 0/1 | 1/3 | 2/4 | 2/2 |
| LymphopeniaBlood and lymphatic system disorders | 0/1 | 0/2 | 1/3 | 1/7 | 0/2 | 0/1 | 0/1 | 0/2 | 1/1 | 1/3 | 1/4 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/1 | 1/2 | 3/3 | 1/7 | 2/2 | 0/1 | 1/1 | 0/2 | 1/1 | 1/3 | 0/4 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/1 | 0/2 | 2/3 | 2/7 | 0/2 | 0/1 | 0/1 | 1/2 | 1/1 | 0/3 | 0/4 | 1/2 |
| Cerumen impactionEar and labyrinth disorders | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| Ear painEar and labyrinth disorders | 0/1 | 0/2 | 1/3 | 1/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 1/3 | 0/4 | 0/2 |
| Ear pruritusEar and labyrinth disorders | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| VertigoEar and labyrinth disorders | 0/1 | 0/2 | 0/3 | 0/7 | 0/2 | 0/1 | 1/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| Ocular hyperaemiaEye disorders | 1/1 | 0/2 | 1/3 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/1 | 0/3 | 0/4 | 0/2 |
| Abdominal pain upperGastrointestinal disorders | 1/1 | 1/2 | 0/3 | 1/7 | 0/2 | 0/1 | 0/1 | 0/2 | 1/1 | 0/3 | 2/4 | 0/2 |
Full Analysis Set included all enrolled participants who took at least 1 dose of study drug in the study. The data for this study are summarized by integrating the parent (NCT01659255) study data and rollover study data.
| Age, Categorical(Participants) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 0 | 3 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 11 |
| >=65 years | 0 | 3 | 4 | 0 | 1 | 2 | 2 | 0 | 2 | 3 | 1 | 18 |
| Sex: Female, Male(Participants) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 6 |
| Male | 1 | 2 | 6 | 2 | 1 | 2 | 1 | 1 | 3 | 2 | 2 | 23 |
| Race/Ethnicity, Customized(Participants) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — White | 2 | 3 | 5 | 2 | 0 | 2 | 2 | 1 | 2 | 4 | 2 | 25 |
| Race — Other | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity — Not Hispanic or Latino | 2 | 3 | 7 | 2 | 1 | 2 | 2 | 1 | 3 | 4 | 2 | 29 |
| Region of Enrollment(participants) | Tirabrutinib 80 mg Once Daily (CLL) | Tirabrutinib 160 mg Once Daily (CLL) | Tirabrutinib 320 mg Once Daily (CLL) | Tirabrutinib 400 mg Once Daily (CLL) | Tirabrutinib 500 mg Once Daily (CLL) | Tirabrutinib 600 mg Once Daily (CLL) | Tirabrutinib 300 mg Twice Daily (CLL) | Tirabrutinib 160 mg Once Daily (NHL) | Tirabrutinib 320 mg Once Daily (NHL) | Tirabrutinib 480 mg Once Daily (NHL) | Tirabrutinib 600 mg Once Daily (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 2 | 2 | 3 | 2 | 0 | 2 | 1 | 1 | 2 | 4 | 1 | 20 |
| France | 0 | 1 | 4 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2015 to primary completion in Dec 2020, 63 months.
Results were first posted in Mar 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirabrutinib